Cardiogenic shock has been linked to a heightened risk of morbidity and mortality. TEER, it seems, may be able to help provide patients with some relief.
The new analysis, published in JACC: Heart Failure, focused on patient data from the renowned COAPT trial.
New two-year findings, presented at TVT 2021, suggest that the Watchman FLX device is a safe alternative to long-term oral anticoagulation therapy.
Lead author John Forrest, MD, a cardiologist at Yale School of Medicine, presented the findings at TVT 2021. He noted that it felt great to finally return to in-person conferences after COVID kept people at home for so long.
Discharge medications after LAAO made no impact on the presence of device-related thrombus, researchers found.
Hoping to shed new light on the debate between DOACs and VKAs, researchers in France examined data from more than 24,000 TAVR patients.
The 3-in-1 offering includes an introducer sheath, positioning balloon and RF puncture dilator.
A team of cardiologists evaluated echocardiography data from more than 3,000 U.S. patients.
The risk of in-hospital mortality, for instance, increased considerably when patients underwent TAVR and a mitral procedure.
When it comes to the risk of structural valve deterioration, however, one treatment option clearly outperforms the other.
The new analysis, published in the Journal of the American Heart Association, examines the connection between CHD and stroke risk from multiple angles.
Patients with Crohn’s disease and ulcerative colitis can safely undergo TAVR, researchers at the Cleveland Clinic have confirmed in a new analysis.